secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055087
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q1 net loss $6.8M; breast cancer patient stays on ALG.APV-527 >11 months
-------------------------------------------------------------------------------

- Net loss $6.8M ($9.95 per share) vs net income $2.8M ($17.38 per share) in Q1 2023.
- Cash $10.3M at March 31, 2024; pro forma $14.3M after April equity raise.
- Heavily pretreated breast cancer patient in ALG.APV-527 Phase 1 achieved stable disease, remains on therapy >11 months, safely transitioned to higher dose.
- APVO436 Phase 1b/2 frontline AML dose optimization trial initiation expected Q2 2024; partnered with Prometrika.
- R&D expenses down $0.4M to $3.8M; G&A down $0.4M to $3.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/0000950170-24-055087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024055087/apvo-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer